Institutional members access full text with Ovid®

Share this article on:

Agomelatine Versus Venlafaxine XR in the Treatment of Anhedonia in Major Depressive Disorder: A Pilot Study

Martinotti, Giovanni MD, PhD*; Sepede, Gianna MD, PhD*; Gambi, Francesco MD, PhD*; Di Iorio, Giuseppe MD*; De Berardis, Domenico MD, PhD; Di Nicola, Marco MD, PhD; Onofrj, Marco MD*; Janiri, Luigi; Di Giannantonio, Massimo MD*

Journal of Clinical Psychopharmacology: August 2012 - Volume 32 - Issue 4 - p 487–491
doi: 10.1097/JCP.0b013e31825d6c25
Original Contributions

Abstract: The primary aim of the present study was to compare the effects of agomelatine (AGO) and venlafaxine XR (VLX) on anhedonia in patients with major depressive disorder. Secondary end points were to test its antidepressant and anxiolytic efficacy.

Sixty patients were enrolled and randomly assigned to two different treatments: AGO (25-50 mg/d; n = 30 subjects) or VLX (75-150 mg/d, n = 30 subjects). Psychopathological assessment was performed at baseline and after 8 weeks of treatment with the Snaith Hamilton Rating Scale (SHAPS), the Hamilton Depression Rating Scale, the Hamilton Anxiety Rating Scale, and the Clinical Global Impression for anhedonia, depression, anxiety, and global improvement, respectively.

Both groups showed a significant reduction in time for the SHAPS, the Hamilton Depression Rating Scale, and the Hamilton Anxiety Rating Scale. A significant between-group difference was observed for SHAPS scores: patients treated with AGO showed a more relevant reduction compared with that in VLX-treated patients. Moreover, only patients treated with AGO showed a statistically significant improvement in Clinical Global Impression scores.

In this study, AGO showed significantly greater efficacy on anhedonia and similar antidepressant efficacy to the serotonin-norepinephrine reuptake inhibitor VLX in patients with major depressive disorder during an 8-week treatment period. Anhedonia has been considered a potential trait marker related to vulnerability for depression. Therefore, the efficacy of AGO on this dimension holds particular importance in the treatment of patients with anhedonic features.

From the *Department of Neuroscience and Imaging, “G. D′Annunzio” University of Chieti, Chieti; †Institute of Psychiatry, Catholic University Medical School, Rome; and ‡National Health Trust, Department of Mental Health, Teramo, Italy.

Received May 20, 2011; accepted after revision November 29, 2011.

All authors contributed to the study and have approved the final manuscript.

Reprints: Gianna Sepede, MD, PhD, Department of Neuroscience and Imaging, ITAB-Institute for Advanced Biomedical Technologies, University “G. D’Annunzio” of Chieti, Via dei Vestini 33, 66013 Chieti Scalo, Chieti, Italy (e-mail: gsepede@libero.it; g.sepede@unich.it).

Funding for this study was provided by the Department of Neuroscience and Imaging, “G. D’Annunzio” University of Chieti, Chieti, Italy. No pharmaceutical and industry support was used in this study.

© 2012 Lippincott Williams & Wilkins, Inc.